Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)()

First-line therapy for higher-risk myelodysplastic syndromes (MDS) includes decitabine (DAC) or azacitidine (AZA). Variables have not identified differential response rates between these. We assessed the influence of patient sex on outcomes including overall survival (OS) in 642 patients with higher...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Leuk Lymphoma
Hoofdauteurs: DeZern, Amy E., Zeidan, Amer M., Barnard, John, Hand, Wesley, Al Ali, Najla, Brown, Francis, Zimmerman, Cassie, Roboz, Gail J., Garcia-Manero, Guillermo, Steensma, David P., Komrokji, Rami S., Sekeres, Mikkael A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2016
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5394924/
https://ncbi.nlm.nih.gov/pubmed/27774847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1246726
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items